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Summary 5 
Bone mineral density declines with increasing older age. We examined the levels of 6 
circulating factors known to regulate bone metabolism in healthy young and older adults. 7 
The circulating levels of dickkopf-1, osteocalcin, osteoprotegerin and sclerostin were 8 
positively associated with WBMD in older adults, despite the average WBMD being lower 9 
and circulating dickkopf-1, osteoprotegerin and sclerostin being higher in old than young.   10 
  11 
 3 
Abstract 1 
Purpose: To investigate the relationship between whole-body bone mineral density 2 
(WBMD) and levels of circulating factors with known roles in bone remodelling during 3 
‘healthy’ ageing. 4 
Methods: WBMD and fasting plasma concentrations of dickkopf-1, fibroblast growth factor-5 
23, osteocalcin, osteoprotegerin, osteopontin and sclerostin were measured in 272 older 6 
subjects (69 to 81 years; 52% female) and 171 younger subjects (18-30 years; 53% female).  7 
Results:  WBMD was lower in old than young. Circulating osteocalcin was lower in old 8 
compared with young, while dickkopf-1, osteoprotegerin and sclerostin were higher in old 9 
compared with young.  These circulating factors were each positively associated with 10 
WBMD in the older adults and the relationships remained after adjustment for covariates (r-11 
values ranging from 0.174 to 0.254, all p<0.01). In multivariate regression, the body mass 12 
index, circulating sclerostin and whole-body lean mass together accounted for 13.8% of the 13 
variation with WBMD in the older adults. In young adults, dickkopf-1 and body mass index 14 
together accounted for 7.7% of variation in WBMD. 15 
Conclusion: Circulating levels of dickkopf-1, osteocalcin, osteoprotegerin and sclerostin are 16 
positively associated with WBMD in community-dwelling older adults, despite the average 17 
WBMD being lower and circulating dickkopf-1, osteoprotegerin and sclerostin being higher 18 
in old than young. 19 
 20 
21 
 4 
Introduction 1 
Progressive loss of bone mineral density (BMD) in older age leads to osteoporosis as the 2 
balance of bone remodelling favours resorption of mineralised extracellular matrix over 3 
formation. This common change is characterized by ‘micro-architectural’ deterioration of 4 
bone tissue and increases the risk of fracture [1]. Circulating factors influencing bone 5 
development have been implicated in the age-related changes to BMD. This includes 6 
regulatory factors released from osteoblasts and osteocytes involved in bone formation and 7 
from osteoclasts with bone resorption, which can enter the circulation where their 8 
concentrations may be related to BMD in older age. 9 
Some of the candidate circulating factors possibly related to BMD include osteoprotegerin 10 
(OPG), which is expressed by osteocytes and osteoblasts and can reduce production of 11 
osteoclasts by binding receptor activator of nuclear factor kappa-B ligand (RANKL) [2]. 12 
Osteocalcin (OC) is a major non-collagen protein of the bone matrix secreted by osteoblasts 13 
for bone formation, but released from the matrix during bone resorption [3]. Dickkopf-1 14 
(DKK1) [4] and sclerostin, released primarily by osteocytes [5], negatively regulate bone 15 
formation and have emerged as therapeutic targets to tackle osteoporosis [6]. Fibroblast 16 
growth factor 23 (FGF23) is produced by a variety of cell types, including osteoblasts and 17 
osteocytes, and released into the circulation where it acts on the kidney to increase 18 
excretion of phosphate and reduce production of 1-25 OH Vitamin D [7]. Osteopontin (OPN) 19 
is an extracellular matrix protein released by osteoblasts, osteocytes and osteoclasts to 20 
facilitate bone resorption [8].  21 
It remains unclear how the combination of these circulating markers of bone turnover are 22 
related to BMD in older age. Therefore, the purpose of this study was to compare plasma 23 
concentrations of these markers between recreationally active, community dwelling older 24 
adults and a reference group of young adults, and to examine the association of these with 25 
whole-body bone mineral density (WBMD). It was hypothesised that older adults would 26 
have higher circulating levels of factors related to bone resorption compared with young, 27 
and higher circulating markers of bone resorption were expected to be associated with 28 
lower BMD in old age.  29 
 30 
 5 
Materials and Methods 1 
Study Design 2 
The cross-sectional European multi-centre MYOAGE cohort consists of relatively healthy 3 
older men and women (aged 69 to 81 years) and young adults (aged 18-30 years) [9]. The 4 
study was approved by ethics committees at each institute and written informed consent 5 
was obtained from all participants. Participants were recruited by advertisement in 6 
newspapers, the University of the Third Age and Association of Emerti. All measurements 7 
were performed according to standard operating procedures that had been unified at the 8 
study centres and data collection was ceased through December-March and July-August. 9 
Volunteers were excluded if: dependent living, unable to walk a distance of 250 m, presence 10 
of morbidity (such as neurologic disorders, metabolic diseases, rheumatic diseases, heart 11 
failure, severe chronic obstructive pulmonary disease and hemocoagulative syndromes), 12 
immobilization for one week during the last three months and orthopaedic surgery during 13 
the last two years or still causing pain or functional limitations. The inclusion and exclusion 14 
criteria were designed to ensure the selection of relatively healthy participants and to 15 
minimize the confounding effect of comorbidity on sarcopenia [9] and we recorded the use 16 
of bisphosphonates, calcium and vitamin D supplements. The present study included 443 17 
participants (Leiden, The Netherlands (young; n=35, old; n=75); Jyvaskyla, Finland (young; 18 
n=34, old; n=65); Tartu, Estonia (young; n=39, old; n=60), Paris, France (young; n=35, old; 19 
n=30) and Manchester, UK (young; n=28, old; n=42)) with complete BMD and bloods results. 20 
 21 
Dual-energy X-ray absorptiometry 22 
A whole body scan was performed using DXA while the participants lay supine, as previously 23 
reported [9] (The Netherlands: Hologic QDR 4500, version 12.4, Hologic Inc., Bedford, MA, 24 
USA; Finland: Lunar Prodigy, version en-Core 9.30; Estonia: Lunar Prodigy Advanced, version 25 
en-Core 10.51.006; France: Lunar Prodigy, version encore 12.30; United Kingdom: Lunar 26 
Prodigy Advance, version enCore 10.50.086). A trained technician completed the daily 27 
equipment calibration and the DXA scans according to local and manufacturers’ quality 28 
control procedures. Participants wore a light cotton garment to reduce effects of clothing 29 
absorption on the scanning results. The whole-body lean mass, fat mass and the WBMD 30 
were recorded after manual adjustment of the regions of interest carried out offline. 31 
 6 
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Blood sample analysis 2 
Blood samples were collected from a vein in the forearm into vacutainer EDTA tubes in the 3 
morning when participants were in a fasted state. Samples remained at room temperature 4 
for 15-30 min and were then centrifuged for 15 min at 2,000 *g at 4◦ C. The plasma was 5 
collected and stored at -80◦C until analysis. Plasma concentrations of the selected analytes 6 
were determined in the research laboratory in Manchester, UK, using multiplex 7 
immunoassays (Millipore, Billerica, MA, USA).  The manufacturer instructions were followed 8 
and the magnetic bead panels quantified DKK1, OPG, OC, OPN, sclerostin and FGF23 using a 9 
96-well plate after an overnight incubation. The sensitivity of each analyte was 1.4 (DKK1), 10 
1.9 (OPG), 68.5 (OC), 37.7 (OPN), 31.1 (sclerostin) and 9.2 (FGF23) pg/mL. Samples were 11 
processed using a Luminex 200 Bioanalyser and protein concentrations were estimated 12 
using the xPONENT software (Luminex, v.3.1.871). 13 
 14 
Statistical analysis 15 
Participant descriptive characteristics (Table 1) were normally distributed and are presented 16 
as mean ± standard error of the mean (SEM). Comparisons between age and gender were 17 
assessed using multivariate ANOVA. Relationships between body stature, BMI, total body 18 
lean mass and supplement use (independent variables) with WBMD (dependent variable) 19 
were assessed using bivariate Pearson’s product moment correlation. Data for circulating 20 
factors were not normally distributed and are presented as median (25th/75th) centiles. The 21 
results were log-transformed and z-scores calculated by expressing each log-transformed 22 
value as a standard deviation from the mean of the gender-matched young. Z-scores of 23 
WBMD, lean mass and BMI were also calculated for use in subsequent correlation and 24 
regression analysis. Spearman’s rho partial correlations were performed to assess 25 
relationships between the z-score WBMD with z-scores of circulating factors using two 26 
models. The first model included adjustment for country of testing to account for any 27 
systematic differences. The second accounted for the positive correlations we observed 28 
between WBMD and BMI in men and women (r-values ranging from 0.210 – 0.387) and 29 
WBMD and lean mass for men (r-values in men ranging from 0.268 – 0.357, and women 30 
0.085 – 0.099) as well as health status and use of bisphosphonates, calcium or vitamin D 31 
 7 
supplements. Thus, the second model included adjustments for: country of testing, z-score 1 
of lean mass, z-score of BMI, self-reported health and supplement use. A stepwise multiple 2 
linear regression using the self-reported health and supplement use as well as z-scores for 3 
BMI, lean mass and circulating factors was then used to evaluate which combination of the 4 
independent variables was associated with z-score WBMD (dependent variable) in older 5 
adults and in young adults. Data was analysed using SPSS for Windows (v.21; IBM, USA) and 6 
significance accepted as p<0.05. 7 
 8 
Results 9 
Based on z-scores relative to gender-matched young, 26% of the older participants had 10 
WBMD values between -1.5 to -2.49 below the mean for young and 10.6% were ≥ -2.5 11 
below the mean of young. There was a significant age-by-gender interaction for WBMD z-12 
scores (p<0.0005). 13 
Table 2 shows concentrations of the circulating factors. Compared with young, older 14 
participants had higher concentrations of DKK1, OPG and sclerostin. Concentrations of OC 15 
were significantly lower in old compared with young. OPN and FGF23 did not differ 16 
significantly between young and older participants although this was after removal of 37% 17 
of FGF23 samples [similar proportions of young and old] that fell below the level of assay 18 
detection. Compared with men, women had higher circulating concentrations of OPG, but 19 
lower OPN and sclerostin. There were no significant differences between men and women 20 
for DKK1, FGF23 and OC. Age x gender interactions were found for OC, OPG and sclerostin 21 
(all p<0.05): the difference between young and old in OC, OPG and sclerostin was greater for 22 
men than it was for women. 23 
Table 3 shows the associations between circulating bone regulatory factors and WBMD. 24 
When using z-scores of all variables and including all participants, while adjusting for 25 
country, WBMD was positively associated with DKK1. This association remained significant 26 
after additionally adjusting for lean mass, BMI, self-reported health and supplement use. In 27 
older participants only, DKK1, OC, OPG and sclerostin were positively associated with 28 
WBMD after adjusting for country. This remained the case when additionally adjusting for 29 
lean mass, BMI, self-reported health and supplement use. In younger participants only, 30 
 8 
DKK1 was positively associated with WBMD after adjusting for country as well as when 1 
additionally adjusting for lean mass, BMI, self-reported health and supplement use. 2 
Stepwise multiple linear regression was performed including z-score WBMD as the 3 
dependent variable and independent variables included: self-reported health, supplement 4 
use and z-scores of the variables BMI and lean mass, as well as the z-scores derived from 5 
log-transformed data for DKK1, FGF23, OC, OPG, OPN and sclerostin. Results in the young 6 
showed DKK1 accounted for 5.1% of the variation in WBMD (adjusted r2=0.051, p=0.010), 7 
while DKK1 and BMI accounted for 7.7% of the variation in WBMD (adjusted r2=0.077, 8 
p=0.005). In the old, BMI alone accounted for 8.9% of the variation in WBMD (adjusted 9 
r2=0.089, p<0.0005); BMI and sclerostin together accounted for 12.0% of the variation in 10 
WBMD (adjusted r2=0.120, p<0.0005), while BMI, sclerostin and whole body lean mass 11 
accounted for 13.8% of the variation in WBMD (adjusted r2=0.138, p<0.0005). 12 
 13 
 14 
Discussion 15 
The results of this study showed that circulating factors DKK1, OPG and sclerostin were each 16 
higher in old compared with young, but positively associated with WBMD in older adults. 17 
Circulating OC was lower in old compared with young and positively associated with WBMD. 18 
In multivariate regression, BMI, circulating sclerostin and whole-body lean mass together 19 
accounted for 13.8% of the variation with WBMD in the older adults. In young, DKK1 and 20 
BMI together accounted for 7.7% of variation in WBMD.  21 
Circulating factors associated with whole-body BMD 22 
Five out of the six circulating factors differed in concentration between old and young (Table 23 
2). Of those, DKK1, OC, OPG and sclerostin were identified from both partial correlation 24 
models as associated with WBMD in older participants (Table 3). 25 
Sclerostin and DKK1 are released primarily by osteocytes and inhibit bone formation by 26 
blocking the osteoblast Wnt/β-canenin signalling pathway [4, 10], with sclerostin and DKK1 27 
also stimulating bone resorption through RANKL [11]. Down-regulation of sclerostin [6] and 28 
DKK1 [4, 6] is associated with markedly increased bone formation. For these reasons, an 29 
 9 
inverse association between circulating sclerostin and DKK1 with WBMD would be expected, 1 
but is not entirely what was observed. In line with expectations, our results revealed, on 2 
average, a 1.8 fold higher circulating sclerostin and approximately 1.2-fold higher DKK1 in 3 
old compared with young, which is consistent with an inverse association between 4 
sclerostin and BMD in older age [12] and with results from a small sample of 36 patients 5 
showing an inverse association between DKK1 and lumbar and femur BMD [13]. However, 6 
contrary to expectations, the circulating levels of sclerostin and DKK1 were positively 7 
associated with WBMD in the older participants (Table 3). Similar positive associations 8 
between circulating sclerostin with BMD and bone micro-architecture in old age has been 9 
previously reported [14-17].  10 
Similar to the findings for sclerostin and DKK1, a paradoxical relationship existed for OPG 11 
and WBMD in older adults: we found higher circulating OPG in old compared with young 12 
(Table 2), but circulating OPG was positively associated with WBMD (Table 3). OPG released 13 
by osteocytes and osteoblasts promotes bone formation. It has been shown to protect 14 
against generalised bone resorption by blocking TNFα in models of chronic inflammation 15 
[18] and is considered to be a decoy receptor for RANKL to reduce osteoclast-driven bone 16 
resorption [19]. There are conflicting reports about the direction of association between 17 
circulating OPG and BMD. A study of postmenopausal women of mean age 62 years [20], 18 
and a study of middle aged men [21] reported inverse relationships between BMD and OPG, 19 
while others reported no relationship [22, 23]. Conversely, and in line with the results of the 20 
present work, when adults in their eighth and ninth decades of life were included in the 21 
sample population the relationship between OPG and BMD was positive [24, 25]. These 22 
conflicting results cannot be explained by the differences between studies in skeletal site 23 
examined. Conflicting results may be related to the differences in the age range of the study 24 
samples and possible gender differences. Our results for OPG and sclerostin showed 25 
significant age x gender interactions indicating that the differences between young and 26 
older men were greater than those between young and older women (Table 2). It is already 27 
known that sex hormones can regulate bone turnover and may interact with these 28 
circulating factors [26]. 29 
It is not clear why circulating sclerostin, DKK1 and OPG were positively associated with 30 
WBMD in older age, despite the conflicting overall trend for higher circulating levels and 31 
 10 
lower WBMD in the old. One possibility is that the older, but healthy mature osteocytes 1 
generally release higher absolute levels of sclerostin, DKK1 and OPG into the circulation [27] 2 
[28]. For example, a positive correlation was found for circulating sclerostin with trabecular 3 
density, number and thickness in older men [14, 27], suggesting the more advanced 4 
trabecular resorption in osteoporotic bone leaves fewer mature osteocytes and thus, lower 5 
sclerostin release than healthy older bone. However, analysis of bone biopsies showed 6 
similar sclerostin mRNA levels in young and old despite higher circulating sclerostin levels in 7 
the old [12] which indicates that the age-related differences in circulating sclerostin may not 8 
be due to increased osteocyte sclerostin gene expression, although this does not necessarily 9 
equal protein production [29].  10 
Lower circulating OC was found in old compared with young (Table 2) and, consistent with 11 
this, circulating OC levels were positively correlated with WBMD in the old (Table 3). OC 12 
released by osteoblasts plays a role in bone formation, so the positive correlation with 13 
WBMD may be expected. However, others suggest that higher circulating OC indicates 14 
greater rates of bone resorption because fragments or whole OC protein is released into the 15 
circulation during bone resorption [3]. A previous study of young and middle-aged women 16 
suggested that circulating levels peaked soon after menopause and dropped thereafter, 17 
although levels were higher in those with osteoporosis than those without [30]. 18 
Interestingly, our results also showed a positive association between DKK1 and WBMD in 19 
the young adults from univariate and multivariate analyses. This association may be a 20 
reflection of the numbers of mature osteocytes or related to total bone mass, but more 21 
work is needed to confirm. One previous study of children and adolescents did not find any 22 
association between circulating DKK1 and BMD, but the young included in that study of 23 
youths were in stages of rapid developmental growth, which could present different results 24 
from the steady- state of young adults [31].  25 
 26 
Strengths and limitations 27 
The MYOAGE study included young and older participants relatively free from lifestyle-28 
related comorbidities for their age and the results are therefore indicative of age-related 29 
effects. Nevertheless, the associations identified in this cross-sectional study cannot be 30 
interpreted as causal relationships despite the clear roles for the selected circulating 31 
 11 
markers in bone remodelling. The results for FGF23 showed no significant age- or gender-1 
differences, nor correlations with WBMD, but a large proportion of the results were below 2 
the level of assay sensitivity, so firm conclusions cannot be drawn for this analyte. We have 3 
measured the circulating levels of markers, which may be influenced by release from non-4 
bone cells, so it is not possible to determine the originating cell type. It is possible that 5 
altered renal function can affect the levels of the circulating factors, but markers of renal 6 
function was not included in the present study due to limitation of plasma sample quantity. 7 
A phantom was not used to calibrate the DXA scanners across sites and we did not adjust 8 
the results to derive “standardised” DXA values, as others have done for hip and femur sites 9 
[32]. Instead, all study centres followed the local quality control procedures, including use of 10 
phantoms and daily calibration and the results were adjusted for country of testing to 11 
account for possible systematic differences. 12 
Future studies should determine the reasons for the positive relationship between 13 
circulating sclerostin, DKK1 and OPG with BMD in older adults, despite the old having on 14 
average higher circulating levels of these factors and lower WBMD.  15 
Conclusion 16 
Sclerostin, DKK1, OPG and OC were each positively associated with WBMD in older adults, 17 
despite the average WBMD being lower and circulating DKK1, OPG and sclerostin being 18 
higher in old than young. Multiple linear regression identified BMI, circulating sclerostin and 19 
whole-body lean mass as explaining approximately 14% of all variation on WBMD amongst 20 
older adults. 21 
 22 
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TABLES 1 
 2 
Table 1. Participant descriptive characteristics.  3 
 Old Young p-value 
 Men 
(n=129) 
Women 
(n=143) 
Men  
(n=82) 
Women 
(n=89) 
Age  Gender 
Age 
(years) 
74.6±0.3 74.0±0.3 23.6±0.3 23.2±0.3 <.0005  
Height  
(m) 
1.74±0.01 1.61±0.01 1.81±0.01 1.67±0.01 <.0005 <.0005 
Body mass 
(kg) 
78.8±1.0 65.1±0.8 75.4±1.2 62.4±1.0 <.0005 .018 
BMI 
(kg/m2) 
25.8±0.3 25.2±0.3 23.1±0.3 22.4±0.3 .017 <.0005 
Body fat 
(kg) 
20.1±0.7 22.7±0.6 12.9±0.7 18.8±0.7 <.0005 <.0005 
Lean mass 
(kg) 
55.9±0.6 
 
40.2±0.5 
 
59.9±0.9 
 
41.4±0.6 
 
<.0005 <.0005 
Body fat 
(%) 
25.5±0.6 
 
34.6±0.6 
 
16.6±0.7 
 
29.6±0.7 
 
<.0005 <.0005 
Lean mass 
(%) 
71.9±0.6 
 
63.0±0.6 
 
79.8±0.7 
 
67.2±0.7 
 
<.0005 <.0005 
WBMD 
(g/cm2) 
1.19±0.01 
 
1.04±0.01  1.25±0.01 
 
1.15±0.01 
 
<.0005 .001 
WBMD  
(z-score) 
-0.63±0.10 -1.47±0.11 0.00±0.11 0.00±0.11 <.0005 <.0005 
 4 
Values are mean ± SEM. WBMD: whole-body bone mineral density. 5 
  6 
 13 
Table 2. Circulating markers of bone remodelling in old and young, men and women. 1 
 Old Young p-value 
 Men Women Men Women Age Gender Age    x 
Gender 
DKK1 
(pg.mL-1) 
577.0 ± 
352-804 
575.3 ± 
346-864 
420.6± 
290-627 
494.3 ± 
284-703 
<.0005 .942 .843 
FGF23 
(pg.mL-1) 
113.5 ± 
72-274 
(n=75) 
103.0 ± 
64-211 
(n=87) 
122.9.7 ± 
87-195 
(n=54) 
141.7 ± 
94-225 
(n=60) 
.792 .316 .700 
OC   
(pg.mL-1) 
14160.5 ± 
9911-18708 
16065.4 ± 
11073-19933 
17581.1 ± 
13304-21223 
16733.9 ± 
12013-20715 
<.0005 .880 .036 
OPG 
(pg.mL-1) 
319.2 ± 
229-419 
306.9 ± 
257-392 
159.4 ± 
114-193 
208.5 ± 
160-260 
<.0005 <.0005 <.0005 
OPN 
(pg.mL-1) 
26590.1 ± 
17094-38028 
21350.1 ± 
13971-31255 
24822.5 ± 
16928-35662 
20877.5 ± 
15937-27777 
.700 .009 .184 
Sclerostin 
(pg.mL-1) 
5690.3 ± 
4348-7556 
4147.6 ± 
3349-5159 
3016.1 ± 
2079-3932 
2366.0 ± 
1923-3134 
<.0005 <.0005 .034 
 2 
Values are median ± 25th – 75th percentiles. For FGF23, the n is less than those given in Table 1 due to some 3 
samples having values that were below the level of detection. The n for all other analytes is the same as shown 4 
in Table 1. 5 
 6 
  7 
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Table 3. Associations between circulating bone regulatory factors and whole body bone mineral density.  1 
Correlation 
with z-score 
WBMD 
 all participants 
combined 
Old Young 
Adjustment 
models 
1 2 1 2 1 2 
DKK1 r=.107 
p=.026 
r=.129 
p=.008 
r=.167 
p=.007 
r=.174 
p=.005 
r=.263 
p=.001 
r=.282 
p<.0005 
FGF-23 r=.067 
p=.274 
r=.051 
p=.406 
r=-.095 
p=.235 
r=-.079 
p=.330 
r=-.086 
p=.370 
r=-.130 
p=.182 
OC r=-.124 
p=.010 
r=-.083 
p=.088 
r=.150 
p=.015 
r=.187 
p=.003 
r=-.023 
p=.767 
r=-.008 
p=.916 
OPG r=-.096 
p=.047 
r=-.039 
p=.419 
r=.209 
p=.001 
r=.254 
p<.0005 
r=.081 
p=.297 
r=.055 
p=.484 
OPN r=-.005 
p=.918 
r=-.001 
p=.980 
r=.055 
p=.370 
r=.073 
p=.245 
r=-.120 
p=.124 
r=-.122 
p=.120 
Sclerostin r=-.091 
p=.059 
r=-.075 
p=.126 
r=.241 
p<.0005 
r=.240 
p<.0005 
r=.129 
p=.096 
r=.135 
p=.086 
 2 
Data are shown as spearman’s rho. The circulating bone regulatory factors were log-transformed and their z-3 
scores calculated. The p value indicates the level of significance after statistical analysis. Results were adjusted 4 
for 1) country; 2) country, z-score lean mass, z-score BMI, self-reported health and supplement use. Significant 5 
relationships are highlighted using bold text. 6 
 7 
  8 
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